Oncology Patient Advocacy Spotlight
This week in health care trends, our oncology patient advocacy spotlight includes: cancer drug prices vary between countries, the gap between public and private payment rates is growing, and a study outlines some of the factors in the premium growth slowdown.
A recent study of the prices of more than 30 cancer drugs across 16 European countries found that “Sweden, Switzerland and Germany pay the most for cancer meds, and the U.K., Spain, Portugal and Greece pay the least, among nations recently studied” and suggests that the disparity is “likely to grow”.
This Health Affairs article reports that “The difference between private and public (Medicare and Medicaid) payment rates for inpatient hospital stays widened between 1996 and 2012” and the rates of private payment were about 75% higher than public rates.
Several Factors Responsible for the Recent Slowdown in Premium Growth in Employee-Sponsored Insurance
An analysis of the recent slowdown in premium growth from 2009-2011 has found that “the dominant contributors to the slowdown were factors underlying declining employee enrollment: a sharp downturn in employment in 2009, followed by eroding offer and eligibility rates.”
The articles above are from our dedicated Oncology Patient Advocacy e-magazine. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)